This month

amycretin's oral phase 3 just opened — and most coverage still hasn't caught up

In October 2026, Amycretin — the GLP-1 and amylin combination Novo Nordisk has been building its next chapter around — is in Phase 3. The injectable obesity trial AMAZE 1 started enrolling in February 2026 with 1,150 planned participants. [ClinicalTrials.gov shows AMAZE 9](https://clinicaltrials.gov/search?term=amycretin), the oral formulation Phase 3, just opened for recruitment in September. [Novo's own Phase 3 announcement](https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916348) lays out the program's weight management ambitions: the molecule, now also called zenagamtide by its international nonproprietary name, is in multiple AMAZE studies spanning obesity and type 2 diabetes, with primary completion not expected until June 2029. The context that's been harder to find than the Phase 3 announcement: the Phase 2 data that triggered this level of investment has a feature buried in the efficacy headline — and it's the kind of number that Phase 3 was specifically designed to answer.

The molecule

amycretin pairs glp-1 with amylin — a different satiety signal from glucagon-based combinations

Amycretin is a unimolecular co-agonist of the GLP-1 receptor and the amylin receptor. The GLP-1 half is familiar — it's the same receptor that semaglutide and tirzepatide engage, producing appetite suppression, slowed gastric emptying, and incretin-pathway satiety signaling. The amylin half is less well covered in the current obesity conversation, partly because amylin as a drug isn't new. Pramlintide, an approved synthetic amylin analog, has been in clinical use for type 1 diabetes for nearly two decades. Amylin is cosecreted with insulin from pancreatic beta cells in response to meals and signals satiety through brainstem pathways that operate separately from the incretin axis. [The PubMed literature on amycretin's mechanism](https://pubmed.ncbi.nlm.nih.gov/?term=amycretin) reflects growing interest in combining these two distinct satiety signals. What makes amycretin different from the other dual agonists in the pipeline — survodutide, retatrutide — is which receptor it pairs with GLP-1: amylin rather than glucagon, targeting satiety from a different direction rather than energy expenditure.

The pitch

24% weight loss in phase 2 made amycretin the next-generation obesity story — with context the headlines skipped

Novo Nordisk's positioning on amycretin has been consistent: Phase 2 numbers that put it at the top of the class. The 24.3% weight loss figure from the Phase 1b/2a dose-escalation study — 60mg over 36 weeks, 125 participants, primary endpoint safety — is the number that traveled. For comparison, Wegovy (semaglutide 2.4mg) posted 14.9% weight loss at 68 weeks in its STEP-1 Phase 3 trial; tirzepatide posted 20.9% in SURMOUNT-1. On paper, amycretin's Phase 2 number exceeds both Phase 3 benchmarks. The combination of a strong efficacy signal and a mechanism with real pharmacological depth made amycretin the kind of story that gets positioned as the next horizon while the current generation ages. What the efficacy frame tends to omit: the 24.3% came from a single Phase 2 arm, in a small study not powered for efficacy, and the broader Phase 2 dataset contains a discontinuation figure that deserves equal attention to the weight loss headline.

What the data says

the phase 2 discontinuation rate in high-dose groups reached 34% — that's the number the readout will test

The Phase 1b/2a trial enrolled 125 participants across multiple dose groups, with safety as the primary endpoint. The 24.3% weight loss came from the 60mg arm at 36 weeks, against -1.1% on placebo — a large effect size from a small cohort. [The clinical trial record for amycretin on ClinicalTrials.gov](https://clinicaltrials.gov/search?term=amycretin) reflects what Phase 1b/2a trials are designed to answer: tolerability at dose, not efficacy at scale. In the Phase 2 type 2 diabetes study — 262 participants over 36 weeks — the adverse event discontinuation rate reached 34% in the 20mg and 40mg dose groups. Across all arms, 16.8% of participants stopped due to adverse events. The side effect profile follows GLP-1 class patterns: nausea, vomiting, diarrhea, dose-dependent in severity. A Phase 2 dose-ranging study is precisely designed to find where tolerability limits are, which means these numbers are not unexpected — but they are exactly why Phase 3 matters. The AMAZE program uses refined dosing informed by this data, and the 2029 readout will determine whether that refinement changes the picture at scale.

Early human — PeptideFactCheck stance

the phase 2 signal is real — what phase 3 adds is the tolerability picture at 1,150 people

Amycretin holds PeptideFactCheck's Early human evidence tier. Small, preliminary, or narrow human studies exist — the Phase 1b/2a and Phase 2 T2D trials are real clinical work, the weight loss signal is genuine, and the amylin mechanism has two decades of pharmacological support through pramlintide and the broader amylin biology literature. What Early human means here: the evidence is not mature. The Phase 3 AMAZE program is running precisely because Phase 2 cannot tell you whether the 24.3% weight loss survives at doses that 1,150 participants can tolerate through completion. BioPharma Dive's framing when amycretin entered Phase 3 described Novo as 'searching for a spark' — [that coverage](https://www.biopharmadive.com/news/novo-nordisk-amycretin-phase-3-trial-obesity-wegovy-zepbound/750670/) captures both the clinical potential and the size of what's still unknown. Approval projections point to 2030 at the earliest if the trials succeed. Interesting enough to watch. Too early for the certainty that Phase 2 headlines tend to carry. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.